Filing Flows

Filing Flows › Tarsus Pharmaceuticals (TARS) › Next earnings date

Tarsus Pharmaceuticals (TARS) earnings: beat the estimate

Tarsus Pharmaceuticals (TARS) reported on Nov 3, 2026 and beat the EPS estimate: −$0.87 against −$1.77 (+50.6%). Revenue was $195M for Q3 2026, +64% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+50.6% vs estimate
Beat rate60%

The last report

Tarsus Pharmaceuticals reported revenue of $195M for the third quarter 2026 (+64% Y/Y), net loss $668M. How it makes money → · Every quarter →

Tarsus Pharmaceuticals: EPS against the estimate, last 5 reportsTarsus Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.33−$0.30Nov 25$0.01−$0.20Feb 26−$0.42−$0.16May 26−$0.20−$0.43Aug 26−$1.77−$0.87Nov 26
Latest (Nov 26): Estimate −$1.77, Reported −$0.87.

Tarsus Pharmaceuticals' latest quarter

Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Tarsus Pharmaceuticals beat earnings?

Tarsus Pharmaceuticals (TARS) reported on Nov 3, 2026 and beat the EPS estimate: −$0.87 against −$1.77 (+50.6%).

When does TARS report earnings?

The next date is not set yet.

Does Tarsus Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.